Brincidofovir

Kathryn Dzintars, Pharm.D., BCPS
Brincidofovir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of human smallpox disease in adults and pediatric patients, including neonates
  • Approved by the FDA in June 2021 for the treatment of smallpox through the FDA Animal Rule.
    • It is NOT available for commercial sale, but Chimerix will work globally with public health agencies in the event the medication is needed for a smallpox outbreak.

NON-FDA APPROVED USES

  • Chimerix transferred exclusive rights for the development of brincidofovir for other indications (e.g., adenovirus) to SymBio Pharmaceuticals Ltd in 2019.
    • Any requests for brincidofovir other than for smallpox should be submitted to SymBio.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of human smallpox disease in adults and pediatric patients, including neonates
  • Approved by the FDA in June 2021 for the treatment of smallpox through the FDA Animal Rule.
    • It is NOT available for commercial sale, but Chimerix will work globally with public health agencies in the event the medication is needed for a smallpox outbreak.

NON-FDA APPROVED USES

  • Chimerix transferred exclusive rights for the development of brincidofovir for other indications (e.g., adenovirus) to SymBio Pharmaceuticals Ltd in 2019.
    • Any requests for brincidofovir other than for smallpox should be submitted to SymBio.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: June 23, 2022